Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical pharmaceutical company developing an injection-based treatment against disc herniation. Stayble currently conducts a phase 1b within disc herniation.

LATEST PRESS RELEASES

February 20, 2024 Regulatorisk

Stayble Therapeutics publishes year-end report for 2023

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2023. The report is available as an attached document and on the...

January 5, 2024

Stayble Therapeutics presents the final data from the phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") today presents the final data analysis of the Company's phase IIb study with STA363 against chronic disc-related back...

FINANCIAL CALENDAR

ANNUAL REPORT 2023
17April2024
ANNUAL MEETING 2024
15May2024
INTERIM REPORT Q1 2024
21May2024
INTERIM REPORT Q2 2024
20August2024
INTERIM REPORT Q3 2024
19November2024
INTERIM REPORT Q4 2024
25February2025